If you are currently on medication to treat obsessive-compulsive disorder, you may be eligible to participate in a new study sponsored by the NIMH. Basically, the purpose of the study is to determine if participants benefit from adding Exposure Response Prevention (ERP) Therapy to their existing SRI medication, as well as finding out whether they can then maintain these gains after discontinuing their SRI.
Participants will remain on their current medication and take part in a maximum of twenty-five sessions of ERP Therapy. If there is a substantial reduction in their OCD symptoms after this period, they will then be randomly selected either to have their medication replaced gradually with a placebo, or continue taking their medications. Monitoring of all participants will continue for six months.
I think this is a wonderful opportunity to receive ERP Therapy from some top-notch professionals, as well as be part of a study that is likely to benefit many people. If you’ve undergone ERP Therapy in the past, you may still be eligible.
I’d like to send a big “thank you” to Dr. Seth Gillihan who was kind enough to let me know that recruiting has now begun. If you are interested in learning more, please visit the research study’s comprehensive website, which gives detailed information regarding the study, as well as contact information.
I’m excited this study is underway, and look forward to the results!